Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04311762 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
A Phase 1 study of Lung Cancer Metastatic, sponsored by University of Vermont.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04311762 is a Phase 1 study of Lung Cancer Metastatic that is active but no longer recruiting, run by University of Vermont. The registered enrollment target is 16 participants, below the 366-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04311762, a Phase 1 study of Lung Cancer Metastatic, is active but no longer recruiting, sponsored by University of Vermont.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
Study Locations (1)
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04311762
The ClinicalTrials.gov registry entry for NCT04311762 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 8 other Lung Cancer Metastatic trials with a reported enrollment target (96% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which cisplatin is the first listed.
NCT04311762 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT04311762 about?
NCT04311762 is a clinical study titled "Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer". The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
What is the current status of trial NCT04311762?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-02-01. Estimated completion is 2029-03-01.
What conditions does trial NCT04311762 study?
This clinical trial studies the following conditions: Lung Cancer Metastatic.
What interventions are being tested in trial NCT04311762?
The interventions under investigation include: cisplatin (DRUG).
Who is sponsoring clinical trial NCT04311762?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04311762 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
RECRUITING · Phase 1
-
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RECRUITING · Phase 1
-
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
COMPLETED · Phase 1
-
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RECRUITING
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.